A majority of biopharma professionals deemed clinical research to be the most expensive part of their business and the area of drug development with the most bottlenecks, but they’ve taken different approaches to pursuing cost efficiency, a survey found.

Most professionals who responded — 57 percent — said that clinical research was the most expensive component of their businesses. By contrast, the second most frequent response, drug discovery and development, only came in at 16 percent as the priciest stage.

Forty-five percent of those surveyed said that clinical research was also the drug development stage in which they saw the most bottlenecks, while 22 percent of respondents said that they encountered the most snags during drug discovery and development.

The 113-person survey was conducted in May by Informa Pharma Intelligence and Cambrex.

Read the full survey report here: https://bit.ly/3gC4nzH.